Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized controlled Phase 3 trial of riluzole for spinal cord injury repair
ChiCTR2300074440Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal cord injury (SCI) comparing Intervention arm: riluzole + standard therapy with Control arm: placebo + standard therapy (2 arms). Primary endpoints: ASIA impairment scale, Somatosensory evoked potential (SEP) and 5 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
riluzole
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on ChiCTR2300074440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074440.